9 min read
‒ Poster for GP2 Phase IIb clinical trial final efficacy analysis was presented during the 2020 San Antonio Breast Cancer Symposium (SABCS) today
‒ Phase IIb clinical trial was a prospective, randomized, single-blinded, placebo-controlled, multi-center (16 sites) trial led by MD Anderson Cancer Center
‒ Kaplan Meier analysis of disease free survival for patients treated with GP2 immunotherapy shows 100% survival (0% breast cancer recurrences, p = 0.0338) following surgery and Herceptin treatment over median 5 years of follow-up
‒ Company now preparing to enter a Phase III clinical trial to treat a similar population of moderate to severe (high risk T1, T2-T4) breast cancer patients
View the full release here: https://www.businesswire.com/news/home/20201209005460/en/
https://finance.yahoo.com/news/greenwich-lifesciences-announces-poster-presentation-140500263.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.